Ader Isabelle, Brizuela Leyre, Bouquerel Pierre, Malavaud Bernard, Cuvillier Olivier
Centre National de la Recherche Scientifique, Sphingolipids and Cancer Research Laboratory, Institut de Pharmacologie et de Biologie Structurale, UMR5089, Université Toulouse III Paul Sabatier, Toulouse, France.
Cancer Res. 2008 Oct 15;68(20):8635-42. doi: 10.1158/0008-5472.CAN-08-0917.
Here, we provide the first evidence that sphingosine kinase 1 (SphK1), an oncogenic lipid kinase balancing the intracellular level of key signaling sphingolipids, modulates the transcription factor hypoxia inducible factor 1alpha (HIF-1alpha), master regulator of hypoxia. SphK1 activity is stimulated under low oxygen conditions and regulated by reactive oxygen species. The SphK1-dependent stabilization of HIF-1alpha levels is mediated by the Akt/glycogen synthase kinase-3beta signaling pathway that prevents its von Hippel-Lindau protein-mediated degradation by the proteasome. The pharmacologic and RNA silencing inhibition of SphK1 activity prevents the accumulation of HIF-1alpha and its transcriptional activity in several human cancer cell lineages (prostate, brain, breast, kidney, and lung), suggesting a canonical pathway. Therefore, we propose that SphK1 can act as a master regulator for hypoxia, giving support to its inhibition as a valid strategy to control tumor hypoxia and its molecular consequences.
在此,我们提供了首个证据,即鞘氨醇激酶1(SphK1),一种平衡关键信号鞘脂细胞内水平的致癌脂质激酶,可调节转录因子缺氧诱导因子1α(HIF-1α),即缺氧的主要调节因子。SphK1活性在低氧条件下被刺激,并受活性氧调节。HIF-1α水平的SphK1依赖性稳定由Akt/糖原合酶激酶-3β信号通路介导,该通路可防止其被泛素蛋白酶体途径介导的von Hippel-Lindau蛋白降解。SphK1活性的药理抑制和RNA沉默抑制可防止HIF-1α在几种人类癌细胞系(前列腺癌、脑癌、乳腺癌、肾癌和肺癌)中的积累及其转录活性,提示存在一条经典途径。因此,我们提出SphK1可作为缺氧的主要调节因子,支持将其抑制作为控制肿瘤缺氧及其分子后果的有效策略。